Changchun High-Tech Industry's Subsidiary Grants Yarrow Bioscience Worldwide Rights for Eye Disease Drug; Shares Up 4%

MT Newswires Live12-16

Changchun High-Tech Industry's (SHE:000661) subsidiary, Shanghai Saizeng Medical Technology, agreed to grant Yarrow Bioscience exclusive worldwide rights for the GenSci098 injection project, according to a Shenzhen bourse filing on Tuesday.

The drug is being studied for indications related to thyroid eye disease and Graves' disease.

Saizeng Medical expects to receive an upfront payment of $120 million and milestone payments related to the drug's research and development and commercialization. The pharmaceutical company will also be entitled to $1.37 billion in milestone payments for the exclusive license and royalties of more than 10% for the drug's net sales.

The biopharmaceutical company's shares jumped 4% during afternoon trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591608218?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 13:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591608218","market":"us","top_or_hot":-1,"title":"Changchun High-Tech Industry's Subsidiary Grants Yarrow Bioscience Worldwide Rights for Eye Disease Drug; Shares Up 4%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/000661\">Changchun High-</a>Tech Industry's (SHE:000661) subsidiary, Shanghai Saizeng Medical Technology, agreed to grant Yarrow Bioscience exclusive worldwide rights for the GenSci098 injection project, according to a Shenzhen bourse filing on Tuesday.</p><p>The drug is being studied for indications related to thyroid eye disease and Graves' disease.</p><p>Saizeng Medical expects to receive an upfront payment of $120 million and milestone payments related to the drug's research and development and commercialization. The pharmaceutical company will also be entitled to $1.37 billion in milestone payments for the exclusive license and royalties of more than 10% for the drug's net sales.</p><p>The biopharmaceutical company's shares jumped 4% during afternoon trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Changchun High-Tech Industry's Subsidiary Grants Yarrow Bioscience Worldwide Rights for Eye Disease Drug; Shares Up 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChangchun High-Tech Industry's Subsidiary Grants Yarrow Bioscience Worldwide Rights for Eye Disease Drug; Shares Up 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-16 13:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/000661\">Changchun High-</a>Tech Industry's (SHE:000661) subsidiary, Shanghai Saizeng Medical Technology, agreed to grant Yarrow Bioscience exclusive worldwide rights for the GenSci098 injection project, according to a Shenzhen bourse filing on Tuesday.</p><p>The drug is being studied for indications related to thyroid eye disease and Graves' disease.</p><p>Saizeng Medical expects to receive an upfront payment of $120 million and milestone payments related to the drug's research and development and commercialization. The pharmaceutical company will also be entitled to $1.37 billion in milestone payments for the exclusive license and royalties of more than 10% for the drug's net sales.</p><p>The biopharmaceutical company's shares jumped 4% during afternoon trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0046","symbol_name":"生物疫苗","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2591608218","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591608218","pubTimestamp":1765863713,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Changchun High-Tech Industry's  subsidiary, Shanghai Saizeng Medical Technology, agreed to grant Yarrow Bioscience exclusive worldwide rights for the GenSci098 injection project, according to a Shenzhen bourse filing on Tuesday.The drug is being studied for indications related to thyroid eye disease and Graves' disease.Saizeng Medical expects to receive an upfront payment of $120 million and milestone payments related to the drug's research and development and commercialization. The pharmaceutical company will also be entitled to $1.37 billion in milestone payments for the exclusive license and royalties of more than 10% for the drug's net sales.The biopharmaceutical company's shares jumped 4% during afternoon trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0046":"生物疫苗","BK0057":"长吉图板块","BK0028":"国家队","BK0075":"新三板","BK0239":"医药制造","000661":"长春高新","BK0188":"融资融券"},"translate_title":"长春高新产业子公司授予Yarrow Bioscience眼病药物全球权利；股价上涨4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000661":0.9},"content_text":"Changchun High-Tech Industry's (SHE:000661) subsidiary, Shanghai Saizeng Medical Technology, agreed to grant Yarrow Bioscience exclusive worldwide rights for the GenSci098 injection project, according to a Shenzhen bourse filing on Tuesday.The drug is being studied for indications related to thyroid eye disease and Graves' disease.Saizeng Medical expects to receive an upfront payment of $120 million and milestone payments related to the drug's research and development and commercialization. The pharmaceutical company will also be entitled to $1.37 billion in milestone payments for the exclusive license and royalties of more than 10% for the drug's net sales.The biopharmaceutical company's shares jumped 4% during afternoon trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591608218","isCrawlerRequest":true}